Afstyla Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Afstyla market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as regulatory approvals, product demand, competition from alternatives, pricing strategies, supply chain dynamics, and reimbursement policies.

In the forecast period, growth is expected to be driven by market expansion, the increasing prevalence of hemophilia, rising healthcare expenditure, advancements in gene therapy, government healthcare policies, and patient-centered care models. Key trends in the forecast period include an improved safety profile, a shift towards home-based treatment, personalized medicine approaches, increased use of recombinant therapies, the development of long-acting products, a focus on global market access, and regulatory changes that impact product availability.

The increasing incidence of hemophilia A is expected to drive the growth of the afstyla market. Hemophilia A, a genetic disorder characterized by a deficiency of clotting factor VIII, leads to prolonged bleeding episodes. This growing incidence is largely attributed to improved diagnosis, better reporting, awareness, genetic predisposition, and environmental factors. Afstyla provides long-acting treatment for hemophilia A, improving patient adherence, quality of life, and cost-efficiency. According to the World Federation of Hemophilia, the number of newly identified individuals with bleeding disorders in 2023 was 7,054, including 5,188 with hemophilia. This number is expected to rise significantly by 2025, driving demand for treatments like afstyla.

Rising healthcare expenditure fueling the afstyla market. Increasing healthcare spending - due to an aging population, chronic diseases, medical advancements, and rising drug costs - boosts access to advanced treatments. This increased spending allows more patients to afford specialized care for hemophilia. According to the Office for National Statistics, total healthcare expenditure in the UK rose by 5.6% in nominal terms from 2022 to 2023, further driving demand for advanced therapies like afstyla.

The key trend in the afstyla market is focusing on expanding their manufacturing and research capabilities. Research and development (R&D) centers play a critical role in advancing the therapeutic profile of Afstyla, optimizing manufacturing processes, and developing personalized treatments for hemophilia patients. For example, in September 2022, CSL Limited opened a new R&D center in Marburg, Germany, in partnership with the German government. This facility aims to enhance CSL’s biotechnology capabilities, particularly in immunology, hematology, and vaccines, thereby supporting the growth of Afstyla through continuous innovation in rare disease treatments.

Key player operating in the afstyla market is CSL Behring LLC.

North America was the largest region in the afstyla market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in afstyla report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the afstyla market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Afstyla is a medication used to manage hemophilia A, a bleeding disorder resulting from a deficiency of clotting factor VIII. It is administered intravenously and requires preparation prior to use, helping to prevent or treat bleeding episodes by replenishing this critical clotting factor in the blood.

The primary types of formulation in Afstyla are lyophilized powder and liquid. Lyophilized powder formulations are freeze-dried medications that, when reconstituted with a liquid, form a usable solution. These formulations offer convenience and stability for patients needing hemophilia treatment. Clinical indications include both prophylactic treatment and on-demand treatment. Distribution channels for Afstyla include hospitals, clinics, and retail or specialty pharmacies. The medication is used by adult, pediatric, and geriatric patients.

The afstyla market research report is one of a series of new reports that provides afstyla market statistics, including afstyla industry global market size, regional shares, competitors with a afstyla market share, detailed afstyla market segments, market trends and opportunities, and any further data you may need to thrive in the afstyla industry. This afstyla market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The afstyla market consists of sales of recombinant factor VIII vials and injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.